S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
DIS   130.89 (-1.12%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
DIS   130.89 (-1.12%)
Log in

Horizon Therapeutics News Headlines (NASDAQ:HZNP)

$27.40
-1.08 (-3.79 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$27.24
Now: $27.40
$28.64
50-Day Range
$25.41
MA: $26.96
$28.64
52-Week Range
$16.56
Now: $27.40
$29.44
Volume1.12 million shs
Average Volume1.73 million shs
Market Capitalization$5.11 billion
P/E Ratio14.97
Dividend YieldN/A
Beta0.83

Headlines

Horizon Therapeutics (NASDAQ HZNP) News Headlines

Source:
DateHeadline
Paul W. Hoelscher Sells 20,000 Shares of Horizon Therapeutics PLC (NASDAQ:HZNP) StockPaul W. Hoelscher Sells 20,000 Shares of Horizon Therapeutics PLC (NASDAQ:HZNP) Stock
www.americanbankingnews.com - October 17 at 6:21 PM
Insider Selling: Horizon Therapeutics PLC (NASDAQ:HZNP) CEO Sells 320,174 Shares of StockInsider Selling: Horizon Therapeutics PLC (NASDAQ:HZNP) CEO Sells 320,174 Shares of Stock
www.americanbankingnews.com - October 17 at 6:21 PM
Did Hedge Funds Drop The Ball On Horizon Therapeutics Public Limited Company (HZNP) ?Did Hedge Funds Drop The Ball On Horizon Therapeutics Public Limited Company (HZNP) ?
finance.yahoo.com - October 17 at 6:15 PM
Horizon Therapeutics launches PROTECT trial evaluating KRYSTEXXA in uncontrolled goutHorizon Therapeutics launches PROTECT trial evaluating KRYSTEXXA in uncontrolled gout
seekingalpha.com - October 17 at 1:13 PM
Is Horizon Therapeuticss (NASDAQ:HZNP) 128% Share Price Increase Well Justified?Is Horizon Therapeutics's (NASDAQ:HZNP) 128% Share Price Increase Well Justified?
finance.yahoo.com - October 17 at 1:13 PM
Is Horizon Therapeutics's (NASDAQ:HZNP) 128% Share Price Increase Well Justified?Is Horizon Therapeutics's (NASDAQ:HZNP) 128% Share Price Increase Well Justified?
finance.yahoo.com - October 17 at 1:13 PM
FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Small & Medium Workplaces List for Fourth Consecutive YearFORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Small & Medium Workplaces List for Fourth Consecutive Year
finance.yahoo.com - October 17 at 1:13 PM
Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney TransplantHorizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
finance.yahoo.com - October 17 at 8:13 AM
Horizon Therapeutics PLC (NASDAQ:HZNP) Short Interest UpdateHorizon Therapeutics PLC (NASDAQ:HZNP) Short Interest Update
www.americanbankingnews.com - October 15 at 6:11 AM
Horizon Therapeutics Phase 3 trial finds significant benefit of teprotumumabHorizon Therapeutics' Phase 3 trial finds 'significant benefit' of teprotumumab
seekingalpha.com - October 11 at 2:27 PM
New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye DiseaseNew Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease
finance.yahoo.com - October 11 at 2:27 PM
For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put “Vision First”For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put “Vision First”
finance.yahoo.com - October 10 at 2:03 PM
$333.84 Million in Sales Expected for Horizon Therapeutics PLC (NASDAQ:HZNP) This Quarter$333.84 Million in Sales Expected for Horizon Therapeutics PLC (NASDAQ:HZNP) This Quarter
www.americanbankingnews.com - October 10 at 2:14 AM
Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019
finance.yahoo.com - October 9 at 12:45 PM
Zacks: Brokerages Anticipate Horizon Therapeutics PLC (NASDAQ:HZNP) to Post $0.51 EPSZacks: Brokerages Anticipate Horizon Therapeutics PLC (NASDAQ:HZNP) to Post $0.51 EPS
www.americanbankingnews.com - October 8 at 9:19 PM
New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific SymposiumNew Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium
finance.yahoo.com - October 8 at 8:54 AM
Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for AdoptionHorizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
finance.yahoo.com - October 3 at 4:59 PM
Horizon Therapeutics (NASDAQ:HZNP) Research Coverage Started at Bank of AmericaHorizon Therapeutics (NASDAQ:HZNP) Research Coverage Started at Bank of America
www.americanbankingnews.com - September 26 at 7:52 AM
Horizon Pharma plc (HZNP) Investor Presentation - SlideshowHorizon Pharma plc (HZNP) Investor Presentation - Slideshow
seekingalpha.com - September 13 at 1:53 PM
Horizons (HZNP) Eye Disease Drug Gets FDAs Priority ReviewHorizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review
finance.yahoo.com - September 11 at 12:23 PM
Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in FocusBiotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus
finance.yahoo.com - September 11 at 12:23 PM
Pharma Stocks Hammered As House Proposal Aims To Slash Drug PricesPharma Stocks Hammered As House Proposal Aims To Slash Drug Prices
finance.yahoo.com - September 10 at 12:53 PM
Horizon Therapeutics Teprotumumab nabs accelerated review status for TEDHorizon Therapeutics' Teprotumumab nabs accelerated review status for TED
seekingalpha.com - September 9 at 3:39 PM
Horizon Therapeutics: A Recession Resistant Pick With Upside PotentialHorizon Therapeutics: A Recession Resistant Pick With Upside Potential
seekingalpha.com - September 9 at 3:39 PM
Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
finance.yahoo.com - September 9 at 3:39 PM
Why Is Horizon Therapeutics (HZNP) Down 3.3% Since Last Earnings Report?Why Is Horizon Therapeutics (HZNP) Down 3.3% Since Last Earnings Report?
finance.yahoo.com - September 6 at 1:34 PM
Is Horizon Therapeutics (NASDAQ:HZNP) Using Too Much Debt?Is Horizon Therapeutics (NASDAQ:HZNP) Using Too Much Debt?
finance.yahoo.com - September 2 at 11:35 AM
Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business OfficerHorizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer
finance.yahoo.com - August 29 at 8:28 AM
American Journal of Ophthalmology (AJO) Publishes Review Highlighting Lack of Treatments for Active Thyroid Eye Disease (TED)American Journal of Ophthalmology (AJO) Publishes Review Highlighting Lack of Treatments for Active Thyroid Eye Disease (TED)
finance.yahoo.com - August 19 at 8:06 PM
Horizon Therapeutics plc to Participate in the Morgan Stanley 17th Annual Global Healthcare ConferenceHorizon Therapeutics plc to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
finance.yahoo.com - August 19 at 8:16 AM
Horizon Therapeutics Has Headroom For Value Creation, BMO Says In UpgradeHorizon Therapeutics Has 'Headroom For Value Creation,' BMO Says In Upgrade
finance.yahoo.com - August 14 at 8:08 PM
Horizon Therapeutics plc Collaborates with Rare Disease Advocates to Elevate Resources and Shared Experiences Through Launch of #RAREis™ Community WebsiteHorizon Therapeutics plc Collaborates with Rare Disease Advocates to Elevate Resources and Shared Experiences Through Launch of #RAREis™ Community Website
finance.yahoo.com - August 14 at 8:35 AM
Horizon Therapeutics Plc (HZNP) EVP, Corporate Affairs, CCO Geoffrey M. ...Horizon Therapeutics Plc (HZNP) EVP, Corporate Affairs, CCO Geoffrey M. ...
finance.yahoo.com - August 12 at 11:20 PM
Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue EstimatesHorizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates
finance.yahoo.com - August 7 at 11:13 PM
Horizon Pharma EPS beats by $0.12, beats on revenueHorizon Pharma EPS beats by $0.12, beats on revenue
seekingalpha.com - August 7 at 9:18 AM
Horizon Pharma up 7% premarket on Q2 beat and raied guidanceHorizon Pharma up 7% premarket on Q2 beat and raied guidance
seekingalpha.com - August 7 at 9:18 AM
Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA GuidanceHorizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
finance.yahoo.com - August 7 at 9:18 AM
Horizon Earnings Unexpectedly RiseHorizon Earnings Unexpectedly Rise
finance.yahoo.com - August 7 at 9:18 AM
Horizon Pharma Q2 2019 Earnings PreviewHorizon Pharma Q2 2019 Earnings Preview
seekingalpha.com - August 6 at 11:55 PM
Which Pharmaceutical Stocks Are Outperforming All Other Stocks?Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
finance.yahoo.com - August 6 at 9:04 AM
HZNP Crosses Below Key Moving Average LevelHZNP Crosses Below Key Moving Average Level
www.nasdaq.com - August 5 at 11:42 PM
First Week of HZNP September 20th Options TradingFirst Week of HZNP September 20th Options Trading
www.nasdaq.com - August 3 at 8:19 AM
Horizon Therapeutics plc Appoints Dr. Sue Mahony to Board of DirectorsHorizon Therapeutics plc Appoints Dr. Sue Mahony to Board of Directors
www.marketwatch.com - August 1 at 9:00 AM
Earnings Preview: Horizon Therapeutics (HZNP) Q2 Earnings Expected to DeclineEarnings Preview: Horizon Therapeutics (HZNP) Q2 Earnings Expected to Decline
finance.yahoo.com - July 31 at 11:58 PM
Horizon Therapeutics plc Wins International CSR Excellence Award for Partnership with Perspectives Math and Science AcademyHorizon Therapeutics plc Wins International CSR Excellence Award for Partnership with Perspectives Math and Science Academy
finance.yahoo.com - July 25 at 9:52 AM
Is Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) A Financially Sound Company?Is Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) A Financially Sound Company?
finance.yahoo.com - July 19 at 9:04 AM
Horizon files U.S. application for packet formulation of ProcysbiHorizon files U.S. application for packet formulation of Procysbi
seekingalpha.com - July 18 at 7:16 PM
Horizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in PacketsHorizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets
finance.yahoo.com - July 18 at 7:16 PM
Horizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019Horizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019
finance.yahoo.com - July 16 at 8:41 AM
Commit To Buy Horizon Therapeutics At $15, Earn 9% Using OptionsCommit To Buy Horizon Therapeutics At $15, Earn 9% Using Options
www.nasdaq.com - July 15 at 7:02 PM
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Featured Article: Dogs of the Dow

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel